Incyte (BOVESPA:I1NC34) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

I1NC34 Overzicht aandelen

I1NC34 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	1/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 63.2% onder onze schatting van de reële waarde

De winst zal naar verwachting met 41.13% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Winstmarges (2.5%) zijn lager dan vorig jaar (10.4%)

Grote eenmalige posten die de financiële resultaten beïnvloeden

Incyte Corporation Concurrenten

Blau Farmacêutica

BOVESPA:BLAU3

R$2.6b

Hypera

BOVESPA:HYPE3

R$16.2b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$13.2b

United Therapeutics

NasdaqGS:UTHR

US$16.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Incyte
Historische aandelenkoersen
Huidige aandelenkoers	US$184.68
52 Week Hoogtepunt	US$192.82
52 Week Laag	US$135.90
Bèta	0.73
11 maand verandering	4.58%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	0.098%
5 jaar verandering	n/a
Verandering sinds IPO	15.21%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	I1NC34	BR Biotechs	BR Markt
7D	0%	0.9%	0.7%
1Y	n/a	21.6%	9.6%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe I1NC34 presteerde ten opzichte van de BR Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe I1NC34 presteerde ten opzichte van de BR markt.

Prijsvolatiliteit

Is I1NC34's price volatile compared to industry and market?
I1NC34 volatility
I1NC34 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.1%
Market Average Movement	4.4%
10% most volatile stocks in BR Market	9.1%
10% least volatile stocks in BR Market	2.2%

Stabiele aandelenkoers: De aandelenkoers van I1NC34 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van I1NC34 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1991	2,524	Herve Hoppenot	www.incyte.com

Incyte Corporation, een biofarmaceutisch bedrijf, houdt zich bezig met het ontdekken, ontwikkelen en op de markt brengen van therapeutica voor hematologie/oncologie en ontstekingen en auto-immuniteit in de Verenigde Staten en internationaal. Het bedrijf biedt JAKAFI (ruxolitinib) aan voor de behandeling van myelofibrose met intermediair of hoog risico, polycythemia vera en steroïd-refractaire acute graft-versus-hostziekte; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) voor recidief of refractair diffuus groot B-cellymfoom; PEMAZYRE (pemigatinib), een fibroblastgroeifactorreceptorkinaseremmer die fungeert als oncogene drivers in vloeibare en vaste tumortypes; ICLUSIG (ponatinib) voor de behandeling van chronische myeloïde leukemie en Philadelphia-chromosoom positieve acute lymfoblastische leukemie; en ZYNYZ (retifanlimab-dlwr) voor de behandeling van volwassenen met metastatisch of terugkerend lokaal gevorderd Merkelcelcarcinoom, evenals OPZELURA crème voor de behandeling van atopische dermatitis. Haar producten in klinische fase omvatten retifanlimab in Fase 3 klinische studies voor plaveiselcelcarcinoom van het anale kanaal en niet-kleincellige longkanker; axatilimab, een anti-CSF-1R monoklonaal antilichaam in Fase 2 dat wordt ontwikkeld als therapie voor patiënten met chronische GVHD; INCA033989 om oncogenese af te remmen; INCB160058, dat wordt ontwikkeld als een ziekte-modificerende therapie; en INCB99280 en INCB99318 voor de behandeling van solide tumoren.

Incyte Corporation Samenvatting

Hoe verhouden de winst en inkomsten van Incyte zich tot de beurswaarde?
I1NC34 fundamentele statistieken
Marktkapitalisatie	R$72.88b
Inkomsten(TTM)	R$554.59m
Inkomsten(TTM)	R$21.99b

131.4x

Koers/Winstverhouding

3.3x

P/S-verhouding

Is I1NC34 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
I1NC34 resultatenrekening (TTM)
Inkomsten	US$3.86b
Kosten van inkomsten	US$2.66b
Brutowinst	US$1.20b
Overige uitgaven	US$1.10b
Inkomsten	US$97.30m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Oct 29, 2024

Winst per aandeel (EPS)	0.51
Brutomarge	31.08%
Nettowinstmarge	2.52%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde I1NC34 op de lange termijn?

Bekijk historische prestaties en vergelijking

I1NC34 Overzicht aandelen

Beloningen

Risicoanalyse

Incyte Corporation Concurrenten

BOVESPA:BLAU3

R$2.6b

BOVESPA:HYPE3

R$16.2b

NasdaqGS:BMRN

US$13.2b

NasdaqGS:UTHR

US$16.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Recent updates

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte Corporation Provides Earnings Guidance for 2024

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Incyte Corporation Revises Earnings Guidance for the Year 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa)

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer

Incyte Corporation to Report Q1, 2022 Results on May 03, 2022

Incyte Corporation Provides Revenue Guidance for the Full Year 2022

Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults

Calithera Biosciences, Inc. Enters into A Settlement Agreement and Release with Incyte Corporation

Incyte Announces Health Canada Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Eli Lilly and Company and Incyte Announce Results from an Additional Cohort of 101 Adult Patients from the COV-Barrier Trial

Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis

Incyte Corporation Announces U.S. Food and Drug Administration Extends sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease